SBIR Phase I: An extravascular bipolar catheter for targeted nerve ablation with minimal collateral damage to surrounding tissues

这个小型企业创新研究(SBIR)第一阶段项目的更广泛的影响/商业潜力是治疗心力衰竭患者子集的一种新颖和新兴的方法。尽管有现代的医疗方案和设备疗法，心力衰竭仍影响着600万美国人，仍然是美国死亡和住院的主要原因。建议的系统和方法旨在通过利用已建立的临床准入程序进行大内脏消融术(GSN)来提供一种新的程序和治疗范例。这个小企业创新研究第一阶段项目将开发一种新的、微创、导管输送的静脉手术，用于进行血管外大内脏消融术(GSN)。建议的导管系统利用临床公认的静脉途径进行血管外去神经，同时将对周围其他组织的侧枝(靶外)损害降至最低。该项目的目标包括设计和制作新设备的原型，这些设备将能够实现局部能量输送，并纳入一个表明程序成功的检测系统。台式测试和临床前动物模型研究都将用于获取和消融，验证设备的功能和性能。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel and emerging method for treating a subset of heart failure patients. Despite modern medical regimen and device therapies, heart failure affects 6 million Americans and remains a leading cause of death and hospitalization in the United States. The proposed system and approach aim to provide a novel procedure and treatment paradigm by leveraging an established clinical access procedure for performing Greater Splanchnic Ablation (GSN). The system would enable rapid and wider clinical adoption of the emerging therapy.This Small Business Innovation Research Phase I project will develop a novel, minimally invasive, catheter-delivered, venous procedure for performing extravascular Greater Splanchnic Ablation (GSN). The proposed catheter system utilizes a clinically accepted venous approach in order to perform extravascular denervation, while minimizing collateral (off-target) damage to the other surrounding tissues. The objectives of this project include designing and prototyping new devices that will enable localized energy delivery and incorporate a detection system indicative of procedural success. Both benchtop testing and pre-clinical animal model studies will be used to access and ablate, verifying the function and performance of the device.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.